학술논문
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Document Type
journal article
Author
Source
Journal of Clinical Oncology; 11/1/2018, Vol. 36 Issue 31, p3101-3109, 14p
Subject
Language
ISSN
0732183X